NXTC Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	463 365
Durchschnittsvolumen	286 475
Marktkapitalisierung	32.73M
EPS	$0 ( 2024-03-21 )
Nächstes Ertragsdatum	( $-0.450 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.520
ATR14	$0.0100 (0.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Shaw Kevin G.	Buy	93 900	Employee Stock Option (Right to Buy)
2024-03-29	Richman Michael	Buy	244 400	Employee Stock Option (Right to Buy)
2024-03-29	Myint Han	Buy	93 900	Employee Stock Option (Right to Buy)
2024-03-29	Mayer Timothy	Buy	93 900	Employee Stock Option (Right to Buy)
2024-03-29	Langermann Sol	Buy	93 900	Employee Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 6 167 538 \| Sell: 82 463

Volumen Korrelation

Lang: -0.15 (neutral)

Kurz: -0.87 (strong negative)

Signal:(24.85) Be Aware. Possible trading coming up! (swing)

NextCure Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

NextCure Inc Korrelation - Währung/Rohstoff

-0.37
( neutral )

0.46
( neutral )

0.00
( neutral )

0.30
( neutral )

0.75
( moderate )

-0.50
( weak negative )

NextCure Inc Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-3.68M (0.00 %)
EPS:	$-2.25

FY	2023
Umsatz:	$0
Bruttogewinn:	$-3.68M (0.00 %)
EPS:	$-2.25

FY	2022
Umsatz:	$0
Bruttogewinn:	$-4.48M (0.00 %)
EPS:	$-2.50

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.51

Financial Reports:

No articles found.

NextCure Inc

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Echtzeitaktualisierungen für NextCure Inc [NXTC]

Upcoming Earnings Alert